Artal Participations S.a r.l. bought LXRX

February 17, 2026 · Form 4 insider transaction

Artal Participations S.a r.l. bought 41,289.58 shares of Lexicon Pharmaceuticals, Inc. at $65.00 per share, a transaction worth $2.68M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
41,289.58
Price
$65.00
Total value
$2.68M
RoleDirector, 10% owner
SecuritySeries B Convertible Preferred Stock
Transaction codeA: Grant or award
Transaction dateFebruary 17, 2026
Filing dateFebruary 19, 2026
Shares owned after408,435
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Pursuant to that certain preferred stock purchase agreement (the "Purchase Agreement") with the Issuer, dated as of January 29, 2026, in connection with the underwriter's partial exercise of their option to purchase additional shares of Issuer common stock par value $0.001 per share (the "Common Stock") in an underwritten public offering, Artal Participations S.a r.l. purchased an additional 41,289.58 shares of Issuer Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") at a price of $65.00 per share. Each share of Preferred Stock will automatically convert into 50 shares of Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible.; These securities are directly held by Artal Participations S.a r.l.; The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.; Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

View the original Form 4 on SEC EDGAR